ArticleNPJ precision oncology2025
EPAS1 increases SDHA to inhibit proliferation of multiple myeloma cells by restoring TCA Cycle.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Histone deacetylases in cancer metabolic reprogramming.Experimental & molecular medicine · 2026Review
- Natural Plant Bioactives as Regulators of Histone Modifications: Bridging Epigenetics and Anticancer Therapy.Phytotherapy research : PTR · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Multiple myeloma (MM) is a hematologic malignancy characterized by monoclonal proliferation of plasma cells. As most patients with MM relapse after multiple lines of therapy, seeking new treatment strategies is an urgent task for current research. We found succinate dehydrogenase subunit A (SDHA) was closely related to prognosis of MM patients. SDHA promoted the tricarboxylic acid (TCA) cycle and inhibited glycolysis. It subsequently repressed the proliferation and invasion of MM both in vitro and in vivo. Endothelial pAS domain protein1 (EPAS1), also known as hypoxia-inducible factor-2α (HIF-2α), is a key transcription factor in response to hypoxia. We found that patients with high EPAS1 expression had a better prognosis. EPAS1 promoted the TCA cycle, suppressed glycolysis, and inhibited the proliferation and invasion of MM both in vitro and in vivo. EPAS1 enhanced SDHA expression by inhibiting HDAC2 mRNA expression and increasing acetylation at the SDHA histone H3K27 site. In conclusion, activating the EPAS1-HDAC2-SDHA axis could restore the TCA cycle as the dominant glucose metabolism pathway in order to inhibit proliferation of MM cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.